Summary of capsaicin-induced dermal blood flow (mean perfusion) after single oral administration of ubrogepant or placebo with capsaicin 300 or 1000 μg/20 μl
| Capsaicin Conc.b (μg/20 μl) | Treatment | N | Percentage Inhibition (90% CI)a | |
|---|---|---|---|---|
| 1 h | 5 h | |||
| 300 | Placebo | 16 | ||
| 0.5 mg | 16 | 22.6 (2.7, 38.4) | 15.5 (-0.8, 29.1) | |
| 5 mg | 14 | 53.4 (40.8, 63.3) | 65.2 (58.3, 70.9) | |
| 40 mg | 16 | 63.4 (54.0, 70.9) | 65.1 (58.4, 70.8) | |
| 1000 | Placebo | 16 | ||
| 0.5 mg | 16 | 27.1 (9.5, 41.3) | 3.1 (-14.7, 18.2) | |
| 5 mg | 14 | 60.8 (50.7, 68.7) | 60.7 (53.3, 67.0) | |
| 40 mg | 16 | 64.9 (56.5, 71.7) | 63.9 (57.3, 69.5) | |
↵a Percentage inhibition of dermal blood flow calculated as (1 − GMR) × 100 percent. Root mean square error on log scale from model: 0.384 at 1 h and 300 μg/20 μl, 0.290 at 5 h and 300 μg/20 μl, 0.345 at 1 h and 1000 μg/20 μl, 0.284 at 5 h and 1000 μg/20 μl.
↵b Capsaicin was applied 0.5 and 4.5 h after administration of ubrogepant.